Back

Ticagrelor monotherapy after percutaneous coronary intervention in patients with concomitant diabetes mellitus and chronic kidney disease: a TWILIGHT substudy

29 August 2021 (07:24 - 07:33)
Organised by:
Congress Presentation Part of: Highlights from the Young in Intervention Adjunctive Pharmacotherapy ESC Premium Access ESC Congress 2021 - The Digital Experience

About the speaker

Photo
Doctor Davide Cao

Humanitas University, Milan (Italy)

4 More presentations in this session

Presentation thumbnail
Risk prediction in patients with classical Low-flow, low-gradient aortic stenosis undergoing TAVI
Doctor S. Ludwig (Hamburg, DE)
Abstract Slides Video
Presentation thumbnail
Implications of ESC-high tthrombotic risk features and ARC-high bleeding risk criteria on clinical outcomes in all-comer patients undergoing PCI
Doctor H. Wang (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
Long-term follow-up of early leaflet thrombosis after transcatheter aortic valve replacement
Doctor M. Hein (Bad Krozingen, DE)
Abstract Slides Video
Presentation thumbnail
Derivation and validation of a pretest probability score for deep vein thrombosis before surgery
Doctor Y. Hamamoto (Kagoshima, JP)
Abstract Slides Video

Access the full session

Session thumbnail
Highlights from the Young in Intervention

The Event

Event poster

ESC Congress 2021 - The Digital Experience

29 August 2021 07:24 CET
You may be interested in
thumbnail
Congress Presentation
A patient with recent non-ST elevation myocardial infarction and percutaneous coronary intervention requiring cancer surgery: what do the guidelines say?
thumbnail
Congress Session
2023 ESC Guidelines for the Management of Acute Coronary Syndromes
thumbnail
Congress Session
Adjunct pharmacology in PCI: beyond antiplatelet therapy, the next chapter

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources